FDA places partial hold on Bright Minds' planned Phase 2 BMB-101 epilepsy trial; shares plunge
- FDA placed a partial clinical hold on Bright Minds' planned U.S. Phase 2 trial of BMB-101 in developmental and epileptic encephalopathies (protocol BMB-101-105).
- The hold cites mouse toxicity findings and insufficient juvenile toxicity data. The company calls the findings incidental and unrelated to BMB-101, and says its other ongoing trials are unaffected.
- The FDA said it will send a full hold letter within 30 days. No timeline for lifting the hold is set.
- Reported shares fell about 52% to $26.20 on Nov 2, from $54.98 on Oct 30.
💡 Points Based on public reports
A hold on a trial that has not started, and shares roughly halve: the market is pricing a pipeline built around one asset. The juvenile toxicology gap is the real issue, because epileptic encephalopathies are pediatric and FDA wants that data first. Calling the mouse findings incidental will not settle it; the full letter within 30 days will.